Articles

Age-Based Screening for Lung Cancer Surveillance in the US

Hee Chul Yang, Austin Chang, Maxime Visa, et al. JAMA Netw Open. 2025 Nov 3;8(11):e2546222

Lung cancer is increasingly diagnosed in never-smokers, suggesting that the current US Preventive Services Task Force (USPSTF) screening criteria using low-dose computed tomography exclude many at-risk individuals, thus raising concerns about their effectiveness and equity. Patients with lung cancer diagnosed from ... Read More

13 May, 2026

Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data

Ling Qi , Mengfei Sun, Weixin Liu, et al. Chin Med J (Engl). 2024 Dec 20;137(24):3108-3116

The aim of this study is to analyze the current burden of esophageal cancer in 185 countries in 2022 and to project the trends up to the year 2050. In 2022, an estimated 511,054 people were diagnosed with esophageal cancer globally, and 445,391 died from the disease. The global ASIR and ASMR for esophageal cancer ... Read More

13 May, 2026

The gut microbiome is associated with disease-free survival in stage I-III colorectal cancer patients

Doratha A Byrd, Victoria Damerell, Maria F Gomez Morales, et al. Int J Cancer. 2025 Jul 1;157(1):64-73

Colorectal cancer (CRC) is the second overall leading cause of cancer death in the United States, with recurrence being a frequent cause of mortality. The gut microbiome, reflected in fecal samples, is likely mechanistically linked to CRC progression and may serve as a non-invasive biomarker. Accordingly, we levera... Read More

13 May, 2026

Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action

Evan Weber, Carlos A Carmona-Gonzalez, Melanie Boucher, et al. Curr Oncol. 2025 May 22;32(6):290

Pathogenic variants in breast cancer predisposition genes are associated with poor clinical outcomes but also offer an opportunity for more individualized therapeutic pathways. Given increasing knowledge, improvements in germline genetic testing efficiency, and the availability of novel systemic targeted treatment... Read More

13 May, 2026

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer

Zoulikha Rezoug , Stephanie P Totten, David Szlachtycz, et al. JAMA Netw Open. 2024 Sep 3;7(9):e2431427

Between 5% and 10% of breast cancer cases are associated with an inherited germline pathogenic or likely pathogenic variant (GPV) in a breast cancer susceptibility gene (BCSG), which could alter local and systemic therapy recommendations. Of 1017 referred patients, 805 were eligible and offered genetic counseling a... Read More

13 May, 2026

Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer

Elham Kazemian , Qianxing Mo , Marco Matejcic, et al. J Natl Cancer Inst. 2025 Dec 1;117(12):2513-2525

Cancer-related fatigue (fatigue) is a common and persistent symptom after cancer treatment, yet the role of genetic susceptibility remains unclear. We used data from a prospective cohort study called the ColoCare Study, conducted over 5 US sites and Germany. Fatigue was assessed at 5 time points using the European ... Read More

13 May, 2026

Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial

Kirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, et al. JAMA Intern Med. 2026 Mar 1;186(3):344-352

Among 23 098 women who completed germline genetic testing (mean age, 54.3 years), 714 (3.1%) carried a PV. Excluding 109 who were previously aware of their PV, the detection rate was 2.6%. PVs were most common in CHEK2 (337) and ATM (101) but less common in higher-penetrance genes (BRCA1, 33; BRCA2, 82; PALB2, 44).... Read More

13 May, 2026

Age-related differences in employment, insurance, and financial hardship among colorectal cancer patients: a report from the ColoCare Study

Karely M van Thiel Berghuijs, Heydon K Kaddas, et al. J Cancer Surviv. 2024 Jun;18(3):1075-1084

Employment and financial hardships are common issues for working-age colorectal cancer patients. We surveyed colorectal cancer survivors to investigate employment, insurance, and financial outcomes by age at diagnosis. There were 202 participants who completed the survey (age: 18-49 (n = 42, 20.8%), 50-64 (n = 79,... Read More

13 May, 2026

Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach

Yoshie Takatori-Shirakami, Mitsue Saito, Kazuhito Yokoyama. Breast Cancer. 2025 Jan;32(1):101-108

In Japan, biennial mammography screening has been recommended for the early detection of breast cancer (BC) in women aged 40 years or above since 2004 by the Ministry of Health, Labor and Welfare. We used a dynamic life table modeling approach to estimate the work productivity of female patients aged 40-64 years d... Read More

13 May, 2026

Financial Difficulty Over Time in Young Adults With Breast Cancer

Sara P Myers, Yue Zheng, Kate Dibble, Elizabeth A Mittendorf, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2446091

Young adults aged 18 to 39 years represent the minority of breast cancer diagnoses but are particularly vulnerable to financial hardship. A total 1008 patients were included (median age at diagnosis, 36 years). Patients' tumors were primarily stage I-II (778), estrogen receptor/progesterone receptor-positive (754)... Read More

13 May, 2026